ANN ARBOR, Mich., November 3, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that its production operations in Vietnam remain fully secure and uninterrupted following the recent series of typhoons that have impacted parts of Southeast Asia.

Kraig Labs confirmed that its spider silk production facilities and infrastructure sustained no damage or disruption, including its mulberry feedstock supplies, from the severe weather events that caused widespread flooding in lowland regions. The Company’s strategic decision made in 2024 to relocate its operations into the protected highlands has proven to be a highly valuable investment in operational resilience and long-term stability.

“Our hearts go out to the many people and businesses across the region who have suffered loss and devastation from these storms. Kraig Labs will be contributing to the relief and recovery efforts, helping those who have been devastated by these disasters,” said Kim Thompson, Founder and CEO of Kraig Labs. “We are deeply grateful that our facilities and personnel are safe, and we remain fully operational. Our highland infrastructure investments have demonstrated their strength and strategic importance.”

Kraig Labs also confirmed that its former facility in Quang Nam province, which has since been closed, was among the areas affected by flooding. However, all Company equipment, staff, and production assets had been permanently and successfully relocated from that site in September, well ahead of the storms.

In addition to moving its infrastructure and production to the highlands, Kraig Labs has implemented a strategy of maintaining multiple, parallel production facilities. This approach not only supports scalability but also serves as an additional safeguard against potential disruptions from natural disasters or other unforeseen events. By building redundancy and flexibility into its production network, the Company continues to strengthen the foundation for long-term growth and reliability.

“With each step forward, we are building greater resilience into every part of our business,” Thompson continued. “Our investments in infrastructure, redundancy, and strategic location have put Kraig Labs in the strongest position in our history. We are confident these facilities will continue to advance our record-setting spider silk production capacity and deliver these amazing materials to consumer markets eager for innovation and disruption.”

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., October 27, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced the promotion of Dr. Xiaoli Zhang to the position of Chief Scientist. This promotion follows a series of groundbreaking scientific achievements under Dr. Zhang’s leadership that are laying the foundation for the next generation of spider silk-based super materials.

Dr. Zhang joined Kraig Labs in October 2024 and was challenged with accelerating the Company’s research program and unlocking new scientific frontiers. Tasked with ambitious and transformative objectives, she not only met but exceeded every milestone in record time, positioning Kraig Labs at the forefront of breakthrough discoveries in advanced fibers and bioengineered materials.

“These achievements are nothing short of revolutionary,” said Kim Thompson, founder and CEO of Kraig Labs. “When Dr. Zhang came on board, we asked her to take on challenges that many believed were impossible. In less than a year, she has led our team to breakthroughs that open the door to entirely new categories of super materials. Her promotion to Chief Scientist reflects both the incredible work she has already done and the even more extraordinary advancements we expect under her continued leadership.”

The innovations driven by Dr. Zhang’s research are now forming the blueprint for a new era of material science, pushing the boundaries of what spider silk can achieve. These advancements promise to redefine performance materials and open new opportunities in higher-margin end markets.

“I am deeply honored by this recognition,” said Dr. Zhang. “The past year has shown us what’s possible when science, vision, and determination come together. What we’ve achieved is just the starting point, we are now poised to pioneer materials that will set entirely new standards for strength, flexibility, and performance. The future for spider silk is brighter than ever.”

With Dr. Zhang leading its research initiatives, Kraig Labs remains firmly positioned as a global leader in spider silk innovation, charting a bold course toward the super materials of tomorrow.

Today’s announcement pairs with the breakthroughs in spider silk production at its operations centers in Southeast Asia, further reinforcing the Company’s leading position in the commercialization of sustainable and cost-effective spider silk.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., October 20, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”, “Kraig” or “Kraig Labs”), a world leader in spider silk technology*, is proud to announce the kickoff of its sixth spider silk production cycle for 2025, featuring the first large-scale deployment of its BAM-1 Alpha, the newest and most advanced evolution of the Company’s recombinant spider silk technology.

Following a year of record technical progress and expanded production, Kraig Labs is entering this next cycle with renewed momentum and enhanced output capability. The BAM-1 Alpha hybrid builds directly upon the Company’s 2024 breakthroughs, delivering stronger performance and higher silk yields while remaining fully aligned with Kraig’s established aggressive production schedule.

“This is an exhilarating moment for Kraig Labs,” said Kim Thompson, Founder and CEO of Kraig Labs. “BAM-1 Alpha represents the next step in the evolution of our spider silk technology. It’s the result of years of focused innovation and the foundation of our future growth.”

This latest production run continues the scale-up of BAM-1 Alpha parental lines, utilizing the same successful framework introduced this summer with the integration of diapause egg management into Kraig Labs’ rearing operations. This integration enables greater production efficiency, smoother logistics, and sustained throughput across multiple production cycles.

As evident by the rapid integration of BAM-1 Alpha into this production cycle launch, this transition to a more advanced hybrid requires no changes to its production schedule or rearing infrastructure, it simply delivers more spider silk per production cycle. The consistency of the Company’s process, combined with the continued evolution of its hybrids, underscores Kraig’s growing leadership in sustainable, high-performance bioengineered super fibers.

“As we move deeper into this next evolution of spider silk, we’re seeing real, measurable results,” Thompson added. “Our team has built a production engine that’s not only scalable, but continuously improving. BAM-1 Alpha is a major leap forward, and it positions us perfectly for the commercial expansion and capacity to meet the growing demand for spider silk.”

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., October 13, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, is proud to announce the Company has succeeded in significantly increasing the production throughput of its recombinant spider silk production platform.   

This increase is the successful result of the Company’s continuous work in the selective breeding of parental strains for its production hybrid silkworms, which is the basis of its recombinant spider silk production system. Kraig’s first successful hybrid, designated the BAM-1, demonstrated hybrid vigor, which increased both cocoon shell weight (a critical measure of silk output) and robustness. That hybrid was created by mating two genetically divergent parental strains. The fielding of the BAM-1 was a major improvement in spider silk production technology. 

Over the past two years, the Company has been using selective breeding to create more advanced parental strains with the goal of increasing hybrid vigor to further increase shell weight. One of these new advanced strains was specifically designed as a replacement for one of the original BAM-1 parental strains.

By mating the strongest of the BAM-1 parental strains with the new advanced strain, the Company has demonstrated measurable hybrid vigor (as measured by cocoon shell weight) of 22%, an increase in hybrid vigor of more than 245% compared to the BAM-1. The new advanced hybrid has been designated as BAM-1 Alpha and will be the Company’s production workhorse moving forward.

“Our small team of researchers continues to outperform our competitors in spider silk R&D and commercial development. The creation of our new BAM-1 Alpha hybrid is the product of our focused vision for large-scale commercialization of spider silk and the dedication of our geneticists to that vision,” said Kim Thompson, Founder and CEO of Kraig Labs. “Frankly, the 250% increase in hybrid vigor over the original BAM-1 has significantly exceeded our expectations and design parameters. The BAM-1 Alpha is producing larger cocoons and more silk, resulting in increased throughput and lower production cost. Though we do not have hard data yet on increases in robustness other than cocoon size and shell weight, our expectation is that general robustness will follow this same pattern.”

Kraig Labs utilizes its proprietary genetically enhanced silkworm technology platform to produce recombinant spider silk. These silkworms spin recombinant spider silk fibers naturally within their cocoons, combining the scalability of traditional sericulture with the superior performance of spider silk proteins.

With BAM-1 Alpha now moving into commercial deployment, Kraig Labs will leverage its multi-facility production infrastructure to integrate this enhanced production hybrid into ongoing manufacturing. This advancement supports the Company’s vision of delivering high-performance spider silk fibers for applications spanning performance textiles, defense, medical, and industrial markets.

This latest development underscores Kraig Labs’ commitment to continuous innovation and its leadership in developing scalable bioengineered materials inspired by nature’s toughest fibers.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., October 6, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that it is preparing to add a third production facility as part of its plans for rapid expansion of recombinant spider silk production.

Over the past 18 months, Kraig Labs has significantly advanced its production model, opening two rearing centers for recombinant spider silk production. The Company is now opening a third center to expand its capacity further.

The Company reports that it is now well underway in identifying a site for this new facility and anticipates finalizing a location within the next 60 days.

This new facility, like the Company’s existing operations, will be established in one of the world’s leading silk production regions. By situating operations within established silk-growing areas, the Company is able to leverage an experienced workforce, robust infrastructure, and a long-standing tradition of excellence in sericulture.

Kraig Labs’ multi-facility strategy is designed to support continuous production. By building redundancies directly into the production chain, the Company has created a stronger and more resilient foundation to meet the current demand and growing market for its recombinant spider silk materials.

“We are looking now for the site of an additional rearing center in order to further expand our production capacity,” said Kim Thompson, Kraig Labs’ founder and CEO. “We expect to lock in the site within the next 60 days. The goal is to further increase our capacity while building in resilience.”

The addition of this new rearing center represents another milestone in Kraig Labs’  expansion of its production capacity and its plans to bring the performance and sustainability benefits of recombinant spider silk to global markets.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., September 25, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced the successful completion of its first simultaneous production cycle across two independent rearing centers. This milestone verifies the Company’s multi-facility production model designed to increase throughput, enhance supply chain resilience, and establish the foundation for continuous recombinant spider silk production.

In this initial two-site cycle, Kraig Labs successfully managed the logistics, material supply, and independent staffing requirements necessary to support parallel operations. Each facility operated with complete autonomy, while maintaining coordinated scheduling and oversight from The Company’s production leadership.

The dual-facility model was executed using a deliberate two-week offset between the start of each cycle. This staggered production schedule enables the seamless integration of outputs from both locations, resulting in a continuous supply of finished cocoons and silkworm eggs, ready to seed subsequent rearing cycles. By synchronizing these operations, Kraig Labs effectively eliminated downtime between cycles, creating a robust and scalable production rhythm.

“The completion of these first parallel batches is a transformative step for our production platform,” said Founder and CEO of Kraig Labs, Kim Thompson. “We have demonstrated that we can operate multiple facilities simultaneously, with independent teams, while maintaining quality and precision across all production parameters. This success validates the scalability of our model and establishes the groundwork for the significant production expansion we have scheduled for the fourth quarter.”

This accomplishment marks a major step forward in The Company’s strategy to scale production and commercialize its revolutionary recombinant spider silk technologies. The dual-facility, offset scheduling approach provides Kraig Labs with enhanced supply chain security, while also substantially increasing total throughput capacity. These efficiencies are designed to support The Company’s long-term production objectives and enable Kraig Labs to meet growing demand from diverse end-use markets.

The Company’s successful execution of its first simultaneous two-facility production cycle, with an emphasis on scaling up parental strains, signals the arrival of a more mature and industrial-scale spider silk manufacturing platform. Kraig Labs anticipates leveraging these capabilities to accelerate growth, enhance efficiency, and expand its position as the global leader in recombinant spider silk production.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., September 19, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that it is actively pursuing the acquisition of an additional silkworm rearing center as part of its ongoing multi-facility expansion strategy to produce its revolutionary recombinant spider silk.

This planned addition builds on the significant production growth and operational advancements achieved over the last 18 months, under the guidance of Dr. Nirmal Kumar, one of the world’s foremost sericulture experts. Kraig Labs relocated its operating headquarters last year to the heart of Asia’s traditional silk-producing regions. Since that time, the Company has delivered record production volumes, streamlined processes, and established a scalable foundation for recombinant spider silk manufacturing.

“The progress we’ve made in expanding our production platform has exceeded expectations,” said Kim Thompson, Kraig Labs’ Founder and CEO. “Dr. Kumar’s leadership has been critical in transforming our sericulture operations into a robust, scalable manufacturing system. As global demand for sustainable super materials continues to accelerate, we are moving forward with the next step in our multi-facility growth strategy – securing additional rearing capacity to bring spider silk to broader markets.”

Through this multi-facility approach, Kraig Labs is creating a production network designed for continuous rearing cycles, greater reliability, and significant capacity increases. By adding new rearing infrastructure, the Company is positioning itself to meet rising global interest from industries ranging from textiles and apparel to defense and consumer goods.

Dr. Kumar will work closely with the Company’s production teams to guide the buildout and integration of the new facility once the acquisition is finalized. His expertise has been central to achieving consistency and efficiency in Kraig Labs’ large-scale recombinant spider silk operations.

“With every expansion, we are moving closer to realizing the full potential of spider silk as a sustainable material solution,” Thompson continued. “This additional facility represents another critical step in our long-term vision to supply the world with affordable, high-quality spider silk.”

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., September 8, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, is happy to announce the appointment of Mr. Kenneth Le as Managing Director of its wholly owned recombinant spider silk production subsidiary, Prodigy Silk Ltd.

Le has been an integral leader in The Company’s Southeast Asian operations for many years, overseeing the expansion of its specialized spider silk rearing and production systems. Under his guidance, Kraig Labs and Prodigy Silk have grown from pilot-scale operations to full-scale commercial rearing centers that continue to set records for spider silk production.

Le brings extensive management experience, operational oversight, and team development expertise. His leadership has been instrumental in creating the foundation for Prodigy Silk’s current production successes, ensuring that the Company’s advanced biotechnology is translated into reliable and sustainable silk output.

“Ken has been at the center of our growth story in Southeast Asia. His ability to combine operational expertise with a deep understanding of our recombinant spider silk technology makes him the ideal choice to lead Prodigy Silk,” said Kim Thompson, Founder and CEO of Kraig Labs. “With Ken at the helm, we expect Prodigy Silk to accelerate production, expand capacity, and deliver on the tremendous promise of our technology.”

As Managing Director, Le will continue to strengthen Prodigy Silk’s production capabilities, optimize rearing operations, strengthen our integration with production partners, and drive forward the Company’s mission of bringing recombinant spider silk to global markets.

“I am honored to take on this new role and to continue building on the successes we’ve achieved,” said Le. “We have an extraordinary team, a proven technology, and the momentum to make spider silk a scalable and commercially viable super material. I look forward to leading Prodigy Silk into this next phase of growth.”

Kraig Labs’ believes Le’s leadership will continue to accelerate the pace of innovation and production, positioning Prodigy Silk as the cornerstone of its commercial spider silk operations in Southeast Asia.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., September 2, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that Dr. Nirmal Kumar, the Company’s lead sericulture expert, has arrived in Southeast Asia to support the production team at its recently established second rearing facility.

Dr. Kumar will work directly with the Company’s operations team on the first production cycle at the new center, ensuring the highest levels of quality and efficiency as Kraig Labs continues to expand its BAM-1 spider silk output. His expertise in silkworm rearing and hybrid development has been instrumental to the Company’s success, and his on-site leadership marks a significant step for Kraig Labs in its transition to continuous production of BAM-1, its first recombinant spider silk hybrid line.

During this time with the team, Dr. Kumar will also oversee the build-out of an expanded BAM-1 egg production center and testing lab, designed to support ongoing scale-up and maintain production continuity across multiple rearing centers. These facilities will form the backbone of the Company’s long-term commercialization strategy as Kraig Labs ramps BAM-1 production to meet growing demand.

Additionally, Dr. Kumar will explore opportunities with secondary processing providers in the region, including spinners capable of supporting downstream applications for recombinant spider silk. As part of this effort, Kraig Labs is currently in discussions with a potential customer regarding a custom order of spider silk thread, a crucial step toward demonstrating the versatility and scalability of BAM-1 in specialty textile markets.

“Having Dr. Kumar on the ground with our production team at this critical stage provides invaluable expertise with our second rearing center now fully online,” said Kim Thompson, Kraig Labs’ Founder and CEO. “His leadership not only strengthens our current BAM-1 production cycle but also sets the stage for the expansion and processing partnerships that will allow us to meet near-term customer opportunities and long-term market demand.”

The Company’s ability to execute on both upstream production and downstream processing highlights its unique position at the intersection of biotechnology and traditional sericulture, as Kraig Labs works to establish spider silk as a commercial reality.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., August 26, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that its two recently established rearing centers, located in the heart of one of Asia’s leading silk-producing regions, have now completely replaced the Company’s original Prodigy Textiles pilot facility as the center of production.

Since opening the first of these two new rearing centers in early 2024, Kraig Labs has produced more recombinant spider silk than in all previous years of the Company’s operations combined. These modern rearing centers provide an optimized production environment, combining advanced biotechnology with the region’s unmatched sericulture expertise, favorable climate, and established infrastructure.

Kraig Labs  has already begun transferring equipment from its original pilot facility to the new commercial production centers, with the process expected to be completed by the end of August. The commercial production facilities will now be operated by the Company’s  wholly owned subsidiary, Prodigy Silk. The Prodigy Textile brand will remain active as a DBA of Kraig Labs.

“This marks a major milestone for Kraig Labs,” said Jon Rice, COO of Kraig Labs. “By moving all of our resources into these purpose-built rearing centers, we are achieving a key expansion objective for 2025, operating in one of the world’s leading silk production locations. With the region’s natural advantages and our cutting-edge science, we are creating the strongest platform yet to deliver the promise of recombinant spider silk to global markets.”

The establishment of these rearing centers is the culmination of nearly a decade of planning. With operations now anchored in one of the world’s foremost silk-producing regions, Kraig Labs is taking a significant step forward in its mission to commercialize spider silk.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com